iNtRON Biotechnology (A048530) Stock Overview
Engages in the development of novel biopharmaceutical drugs in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
A048530 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
iNtRON Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,610.00 |
| 52 Week High | ₩7,010.00 |
| 52 Week Low | ₩2,895.00 |
| Beta | 0.26 |
| 1 Month Change | -3.09% |
| 3 Month Change | -3.86% |
| 1 Year Change | -9.98% |
| 3 Year Change | -54.87% |
| 5 Year Change | -84.17% |
| Change since IPO | -9.75% |
Recent News & Updates
Recent updates
iNtRON Biotechnology (KOSDAQ:048530) Is Due To Pay A Dividend Of ₩100.00
Nov 08
Is iNtRON Biotechnology (KOSDAQ:048530) A Risky Investment?
Nov 03iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business
Nov 15We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt
May 03We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability
Mar 24Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?
Feb 28iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?
Jan 31
iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet
Jan 05What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You
Dec 10iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years
Nov 26Shareholder Returns
| A048530 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.0% | -4.1% | 1.6% |
| 1Y | -10.0% | 35.4% | 147.0% |
Return vs Industry: A048530 underperformed the KR Biotechs industry which returned 35.4% over the past year.
Return vs Market: A048530 underperformed the KR Market which returned 147% over the past year.
Price Volatility
| A048530 volatility | |
|---|---|
| A048530 Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A048530's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A048530's weekly volatility has increased from 10% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 73 | Alek Yoon | www.intron.co.kr |
iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
iNtRON Biotechnology, Inc. Fundamentals Summary
| A048530 fundamental statistics | |
|---|---|
| Market cap | ₩114.13b |
| Earnings (TTM) | -₩8.96b |
| Revenue (TTM) | ₩5.74b |
Is A048530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A048530 income statement (TTM) | |
|---|---|
| Revenue | ₩5.74b |
| Cost of Revenue | ₩2.70b |
| Gross Profit | ₩3.04b |
| Other Expenses | ₩12.00b |
| Earnings | -₩8.96b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -283.37 |
| Gross Margin | 53.05% |
| Net Profit Margin | -156.06% |
| Debt/Equity Ratio | 4.3% |
How did A048530 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 01:39 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
iNtRON Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sangsoo Kim | Goldman Sachs |